Key facts
- Vivere Oncotherapies’s last known valuation is $7.9M (Mar 2022).
- It has raised $10.3M; the latest was Seed Round ($8.9M) in Jul 2025.
- Notable investors include Alumni Ventures, University of California, Pillar VC, Berkeley Frontier Fund, Berkeley — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Vivere Oncotherapies
- ·The full record, as it builds
Funding rounds
No funding rounds for Vivere Oncotherapies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vivere Oncotherapies
Developer of intravenously administered gene therapies designed to improve immunotherapy effectiveness in solid tumours. The company offers engineered delivery vehicles capable of selective tumour replication, multi-antigen immune cell targeting, and expression of therapeutic cargoes that address immunosuppressive tumour environments, enabling patients with immunologically cold solid tumours to access treatments intended to improve therapeutic response and safety.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2022
- Employees
- 8
- Website
- viveretx.com/
- Ownership
- Privately Held (backing)
Vivere Oncotherapies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vivere Oncotherapies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vivere Oncotherapies in its N-PORT filings yet. We sweep new filings monthly.